Search
-
Hemostemix Announces HS 12 – 01 Clinical Trial Completion of Subjects’ Follow-Up Visits at the End of March and Warrants Extended and Repriced
January 28, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) is pleased to…
-
Hemostemix Announces the Bread Contract with the Department of Foreign Affairs, Trade & Development Canada
January 22, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXD) (“Hemostemix” or the “Company”) is pleased to announce…
-
Hemostemix CEO on ACP’s Response to Ischemia in the Circulatory System
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…
-
Co-founder Thomas Smeenk on the benefits of Hemostemix autologous stem cell therapy
In a recent InvestorIntel interview, Peter Clausi speaks with Thomas Smeenk, Co-Founder, President and CEO of Hemostemix Inc.…
-
Hemostemix steps into the new year with capital and its critical clinical study data in hand
With a new management team spearheading Hemostemix Inc. (TSXV: HEM | OTC: HMTXF), the Company started 2021 with…
-
Hemostemix Announces Grant of Stock Options
January 4, 2021 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) announces that, in…
-
Hemostemix Announces Closing of Unit Private Placement
December 31, 2020 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) announces it has closed…
-
Hemostemix Announces Private Placement Update
December 29, 2020 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) announces that it…
-
Hemostemix Announces Corporate Update
December 23, 2020 (Source) — Hemostemix Inc. (TSXV: HEM) (OTC: HMTXF) (“Hemostemix” or the “Company”) The Company is pleased…
-
Hemostemix Inc.
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum…